Publications by authors named "John Corboy"

Claim this Profile
T
Towards a neuroimaging consensus for the workup of adult genetic leukoencephalopathies on behalf of the White Matter Rounds Network: State of Practice.
Alexander D Wong, Laura Airas, Enrique Alvarez, Jack Antel, David Araujo, John R Corboy

AJNR Am J Neuroradiol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic Accuracy of Oligoclonal Bands for CNS Autoimmune Disorders in Acutely Ill Adults.
Jarrett Leech, Brian M Sauer, Amiran Baduashvili, John R Corboy, Thomas Edward Ragole

Neurol Clin Pract· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
West Nile Virus Neuroinvasive Disease in Patients Treated With Anti-CD20 Therapies.
Rumyar V Ardakani, Paul Daniel Crane, Daniel M Pastula, Lakshmi Chauhan, Elizabeth Matthews, John R Corboy

Neurol Clin Pract· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial.
John R Corboy, Robert J Fox, Gary Cutter, Eric Engebretson, Aaron Miller

Mult Scler· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cross-disease resource of living human microglia identifies disease-enriched subsets and tool compounds recapitulating microglial states.
John F Tuddenham, Mariko Taga, Verena Haage, Victoria S Marshe, Tina Roostaei, John Corboy

Nat Neurosci· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Escalation to Anti-CD20 Treatment for Multiple Sclerosis Following Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.
Andrew B Wolf, John R Corboy

Neurol Clin Pract· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
De-escalation and Discontinuation of Disease-Modifying Therapies in Multiple Sclerosis.
Robert H Gross, John Corboy

Curr Neurol Neurosci Rep· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential Diagnosis of Suspected Multiple Sclerosis in Pediatric and Late-Onset Populations: A Review.
Le H Hua, Andrew J Solomon, Silvia Tenembaum, Antonio Scalfari, Àlex Rovira, John R Corboy

JAMA Neurol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shifting patterns of multiple sclerosis treatment in a highly prevalent United States population.
Sue Kwon, Stefan Sillau, John R Corboy, Kavita V Nair, Aaron M Carlson

Ann Clin Transl Neurol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis-Variations in Real-World Experience.
Andrew B Wolf, Enrique Alvarez, John R Corboy

JAMA Neurol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 mRNA vaccination induces an antigen-specific T cell response correlating with plasma interferon-gamma in B cell depleted patients.
Tyler L Borko, Ryan Baxter, Berenice Cabrera-Martinez, Eagappanath Thiruppathi, Maite Sabalza, John R Corboy

J Neuroimmunol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential diagnosis of suspected multiple sclerosis: an updated consensus approach.
Andrew J Solomon, Georgina Arrambide, Wallace J Brownlee, Eoin P Flanagan, Maria Pia Amato, John R Corboy

Lancet Neurol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial.
John R Corboy, Robert J Fox, Ilya Kister, Gary R Cutter, Charity J Morgan

Lancet Neurol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TMEM106B Puncta Is Increased in Multiple Sclerosis Plaques, and Reduced Protein in Mice Results in Delayed Lipid Clearance Following CNS Injury.
Bridget Shafit-Zagardo, Simone Sidoli, James E Goldman, Juwen C DuBois, John R Corboy

Cells· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis.
Britney Barrera, Haley Simpson, Eric Engebretson, Stefan Sillau, Brooke Valdez, John R Corboy

Ann Clin Transl Neurol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenging Cases in Neuroimmunology.
Anna A Shah, Andrew B Wolf, Anthony Declusin, Kyle Coleman, Ryan Kammeyer, John R Corboy

Semin Neurol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Curriculum Innovations: Virtual Didactics as a Tool for Harmonizing Education About Rare Topics in Neuroimmunology.
John Peters, Jeffrey A Cohen, John R Corboy, Sarah E Hopkins, Le H Hua

Neurol Educ· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions.
Enrique Alvarez, Kavita V Nair, Stefan Sillau, Ian Shelton, Rebecca Seale, John Corboy

Mult Scler J Exp Transl Clin· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis.
Brandi L Vollmer, Andrew B Wolf, Stefan Sillau, John R Corboy, Enrique Alvarez

Front Neurol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls.
Enrique Alvarez, Kavita V Nair, Brian D Hoyt, Rebecca A Seale, Stefan Sillau, John R Corboy

Mult Scler Relat Disord· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis: Should We Stay or Should We Go?
Eva M M Strijbis, Anne Kerbrat, John R Corboy

JAMA Neurol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.
Amanda L Piquet, John R Corboy, Timothy L Vollmer

Ther Adv Neurol Disord· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2019-2020: A Message From the Editors to Our Reviewers.
John R Corboy, Elaine C Jones, Richard L Barbano, David C Anderson

Neurol Clin Pract· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate.
Justin M Honce, Kavita V Nair, Brian D Hoyt, Rebecca A Seale, Stefan Sillau, John R Corboy

Front Neurol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Bruce A C Cree, Myla D Goldman, John R Corboy, Barry A Singer, Edward J Fox

JAMA Neurol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis